Skip to main content
SpringerLink
Log in

Rotigotine is effective for depressive symptoms accompanying periodic limb movement disorder or restless legs syndrome

  • Case Report
  • Published:
Sleep and Biological Rhythms Aims and scope Submit manuscript

Abstract

We report two cases who had been diagnosed with major depression, but found to have periodic limb movement disorder (PLMD) or restless legs syndrome (RLS) as major disorder. Both patients had difficulties in occupational and/or daily lives. In neither case, antidepressants were effective in symptom remission. In contrast, rotigotine transdermal patch was effective not only for core symptoms of PLMD or RLS but also for accompanying depressive symptoms. Since PLMD and RLS are associated with dopaminergic dysfunction etiologically, a dopamine receptor agonist rotigotine might be a good choice for patients with PLMD or RLS accompanying depression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. American Academy of Sleep Medicine. International classification of sleep disorders. 3 ed. Darian, IL: American Academy of Sleep Medicine; 2014.

  2. Hornyak M, Scholz H, Kohnen R, et al. What treatment works best for restless legs syndrome? Meta-analyses of dopaminergic and non-dopaminergic medications. Sleep Med Rev. 2014;18:153–64.

    Article  Google Scholar 

  3. Hori H, Kunugi H. Dopamine agonist-responsive depression. Psychogeriatrics. 2013;13:189–95.

    Article  Google Scholar 

  4. Wang HT, Wang L, He Y, Yu G. Rotigotine transdermal patch for the treatment of neuropsychiatric symptoms in Parkinson’s disease: a meta-analysis of randomized placebo-controlled trials. J Neurol Sci. 2018;393:31–8.

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Jun Miura

    Present address: Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11 Kitakarasuyama, Setagaya-ku, Tokyo, 1578577, Japan

Authors and Affiliations

  1. Sapporo Hanazono Hospital, 1-30 South 15 West 15, Chuo-ku, Sapporo, 0640915, Japan

    Jun Miura, Ken-Ichi Honma & Sato Honma

  2. Faculty of Pharmaceutical Sciences, Hokkaido University of Science, Sapporo, Japan

    Jun Miura

  3. Research and Education Center for Brain Science, Hokkaido University, Sapporo, Japan

    Ken-Ichi Honma & Sato Honma

Authors
  1. Jun Miura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ken-Ichi Honma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sato Honma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jun Miura.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest.

Informed consent

Written informed consent for publication was obtained from the patients.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Miura, J., Honma, KI. & Honma, S. Rotigotine is effective for depressive symptoms accompanying periodic limb movement disorder or restless legs syndrome. Sleep Biol. Rhythms 20, 315–317 (2022). https://doi.org/10.1007/s41105-021-00364-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s41105-021-00364-3

Keywords

Search

Navigation